Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination.

Next Previous
Trial Profile

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Feb 2016 According to an Immune Response media release, the company has received a Complete Response Letter from the US FDA for its HIV vaccine Remune HIV-1 Immunogen therapeutic vaccine for adults.
  • 28 Jul 2015 According to a media release, Immune Response BioPharma's FDA BLA for Remune in combination with current HAART drugs for the treatment of patients with HIV infections was accepted on 27th March 2015. The PDUFA date has been changed to 26th November 2015.
  • 11 May 2012 Planned patient number for the rollover trial (NCT00021762) is now 60.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top